 |
Guidepoint Global Survey helps Client gain perspective on likely impact on demand from negative announcement about a leading diabetes therapy
|
News
The European Association for the Study of Diabetes (EASD) announced that, according to the data published in the journal Diabetologia, there may be a possible link between the use of Sanofi-Aventis’ Lantus (insulin glargine) and an increased risk of cancer.
CLIENT NEED
Since Lantus is a very popular insulin product generating major revenue sources for Sanofi-Aventis, Guidepoint's Client wanted to gauge the impact of this news on the potential use of Lantus and other competing products by primary care physicians and endocrinologists across the US and Europe.
The Challenge
The Client needed to develop a perspective immediately regarding likely changes in medical care and purchasing patterns as a result of the news.
the solution
Guidepoint was able to help the Client draft a quick doctor survey instrument that could be targeted to these physician groups in both the US and Europe.
The Result
Guidepoint was able to obtain 100 completed survey responses and the Client was able to use the data to test their hypothesis on both near term and long term impact of this news
Client Testimonial
“Our project manager was amazing to work with and was always prepared for our conversations and made the whole process run smoothly. She was able to translate a very complex survey into programming language for our programmers and had great suggestions about the design and layout of the survey, taking into account our target audience — surgeons and physicians.
We are extremely satisfied with the product we got here, and have already been recommending Guidepoint to our other Clients. Thank you for great work on this.”
- Analyst at a large investment firm
